Introduction
============

Western society experienced a marked nutritional transition during the past century. Multiple factors, stemming primarily from the industrial revolution and mass urbanization, have driven the nutritional profile of the population toward increased consumption of processed and animal-derived foods, saturated fats and refined sugars, while reducing the intake of vegetables, fruits, fibers, and fish ([@B129]; [@B128]). Moreover, these altered eating habits have been associated with larger portion sizes and reduced energy expenditure, making modern lifestyle highly obesogenic ([@B13]; [@B57]; [@B76]; [@B11]). During the same time span, the prevalence of mood disorders has increased significantly in Western countries, even when accounting for evolving diagnostic criteria and other confounding factors ([@B51]; [@B56]). As mechanisms linking diet to mental health become better understood, accumulating evidence suggests that the modern/Western diet may be one of the drivers of this increase ([@B67]; [@B115]).

To address this link, the nascent field of "nutritional psychiatry" ([@B91]) focuses on clinical studies examining the impact of both isolated nutrients and overall quality of diets on the incidence and progression of prevalent psychiatric conditions, most often anxiety and mood disorders. In parallel, the field strives to overcome challenges associated with the combined complexities of human diet and behavior, both of which are difficult to control and evaluate consistently ([@B66]).

Although it is not disputed that the modern lifestyle and nutritional behavior promote a surplus of energy and its storage in the form of expanding adipose tissue ([@B146]), the exact relevance of macronutrient composition--the balance of protein, carbohydrate and fat---to body weight regulation remains under discussion. While some authors argue for a disproportionate contribution of a single type of nutrient to the development of obesity and metabolic disorders, others sustain that such pathologies are not significantly dependent on diet composition, resting instead squarely on a positive energy balance.

[@B14], for instance, have suggested that increased intake of carbohydrates---mainly in the form of glucose/fructose-sweetened beverages, a primary source of added sugars in modern society---is a key driver of the modern pandemic of obesity and metabolic conditions ([@B12]; [@B14]). Indeed, numerous meta-analyses show a positive correlation between sugar consumption and increased risk of insulin resistance, non-alcoholic fatty liver disease (NAFLD), obesity and type 2 diabetes ([@B94]; [@B12]; [@B98], [@B97]; [@B106]; [@B119]; [@B14]; [@B110]). Although such correlations have not been consistently demonstrated when total energy intake is controlled, authors argue that added calories obtained from sugar-sweetened beverages tend to not be compensated elsewhere, as they do not effectively suppress intake of other calories. Mechanistically, increased fructose uptake and metabolism in the liver stimulates *de novo* lipogenesis (DNL), which results in increased intra-hepatic lipid content, leading to increased production and secretion of very low-density lipoprotein and triglycerides. In the long term, these alterations may result in increased fat storage in visceral adipose tissue and ectopic lipid deposition in tissues such as muscle, further contributing to insulin resistance ([@B84]; [@B148]; [@B147]; [@B104]).

On the other hand, as highlighted by [@B72], more recent trends of reduced sugar intake by United States adults have not been accompanied by a reduction in obesity and metabolic disorders. In addition, as mentioned above, most controlled trials using isocaloric diets have not shown a specific contribution of any type of nutrient to obesity, suggesting total energy content is the most relevant variable ([@B69]; [@B72]).

Regarding the role of fat intake, [@B63] recently published a compelling report comparing the long-term effects of 29 types of diet, with varying proportions of fat, carbohydrates and protein, on five different mouse strains. Surprisingly, they found fat content in a diet to be the only factor involved in increased energy intake and adiposity. This observation was explained by a hedonic drive linked to fat, but they did not observe a similar effect with sugar ([@B63]). The fact that a certain diet composition may drive higher energy intake independent of the diet's own energy density adds an additional layer of complexity to the field, particularly in the design and execution of clinical trials.

[@B63] present an interesting discussion on the translatability of this finding, and the feasibility of performing an equivalent study in humans. However, be it due to its higher energy content compared to other nutrients, to its reward value that drives increased caloric intake, or to specific but not yet fully understood signaling and metabolic dysregulation, the impact of increased fat consumption on the development of diet-related diseases has been well documented over the years (for an excellent recent review, see [@B95]). Although controversy remains on the relevance of total fat intake toward body fat accumulation, with several studies indicating no causal relationship ([@B24]; [@B162], [@B163]; [@B156]), excessive energy intake from dietary fat is established as an important factor to increased adiposity ([@B60]; [@B13]).

The fantastic remodeling capacity of adipose tissue allows for adipocyte hypertrophy and hyperplasia in response to nutrient availability and energy surplus. However, under pathological conditions, the need for adaptation exceeds the capacity of the tissue. Hypoxia and adipocyte cell death result in macrophage recruitment and polarization, increasing inflammatory markers, cytokine and chemokine secretion, and dysregulation in free fatty acid (FFA) fluxes ([@B149]).

Increased circulating FFAs and proinflammatory factors are also central to insulin resistance and deregulation of glucose homeostasis, the core aspects of type 2 diabetes mellitus (T2DM) ([@B47]). Obesity and T2DM currently affect a large portion of the world population and are considered a global epidemics, with obesity as the leading risk factor for T2DM ([@B7]).

Notably, the fatty acid composition of diets has been shown to impact their obesogenic profile and overall toxicity. Particularly, enrichment in saturated fatty acids (SFAs) results in a diet that induces greater accumulation of body fat and lower satiety than diets enriched in polyunsaturated fatty acids (PUFAs) ([@B83]; [@B126]; [@B111]; [@B125]). Moreover, excessive SFA consumption was shown to increase SFAs in the circulation, increase expression of genes involved in inflammatory processes in adipose tissue, reduce insulin sensitivity and increase intrahepatic triglyceride content in humans ([@B157]; [@B155]; [@B136]).

Long-term longitudinal studies have linked a low intake of PUFAs and a high intake of cholesterol and SFAs to increased risk of impaired cognitive function and development of dementia, including Alzheimer's disease ([@B70]; [@B107],[@B108], [@B109]; [@B6]; [@B132]). In this context, it has been suggested that metabolic imbalance caused by high-fat diets and a sedentary lifestyle constitutes an important AD risk factor, particularly due to its association with higher levels of plasma FFAs, chronic low grade inflammation, insulin resistance and T2DM ([@B29]). Further, whereas moderate intake of PUFAs at midlife appears to decrease the risk of dementia in aging ([@B80]), saturated and trans-unsaturated fat consumption have been found to be positively associated with increased risk of AD ([@B108]). Adherence to a Mediterranean diet and frequent consumption of fruits and vegetables, fish, and ω-3 (n-3 PUFA) rich oils has been proposed as a factor capable of preventing AD and dementia ([@B139]; [@B4], [@B5]). Moreover, cognitive performance in elderly people (65--90 years old), free from significant cognitive impairment, was better in subjects having high intakes of vegetables, fruits, and vitamins and lower intakes of monounsaturated fatty acids, SFAs, and cholesterol ([@B116]).

A close relationship exists between metabolic syndrome, T2DM and brain dysfunction, encompassing both mood and cognitive disorders ([@B117]; [@B29]; [@B138]; [@B131]). The mechanisms underlying this connection appear largely based on neuroinflammation and dysregulated brain insulin signaling, both of which can result from nutritional imbalance (reviewed in [@B93]; [@B30]; [@B59]; [@B140]).

In the following sections, we focus on data available on the connection between dietary fatty acids and their potential role in mental health, particularly in depressive disorders. We explore how, due to their potential as modulators of neuroinflammation and insulin signaling, fatty acids may be key to the interplay between diet and mental health. We also discuss some of the more recent work exploring how the dopaminergic system, increasingly implicated in the pathophysiology of depression, may be affected by dietary choices.

Human Populational Studies
==========================

While numerous observational studies have been carried out, randomized controlled trials (RCTs) on the relationship between diet and mood disorders are comparatively rare. A meta-analysis conducted in 2014 ([@B79]) examined links between dietary patterns and depression, and found 20 observational studies meeting inclusion criteria, but only one RCT. These authors concluded that 'healthy' diets, including a high intake of fruit, vegetables, fish and whole grains, were inversely correlated with depression. Around the same time, another meta-analysis carried out by [@B130] reached similar conclusions while examining nine observational studies that had depression as the main outcome and eight studies evaluating cognitive function. They found a significant association between adherence to the Mediterranean diet -- a diet pattern similar to what [@B79] classified as healthy -- and lower rates of both depression and cognitive impairment.

Since humans do not typically consume any single type of food in isolation, studies with isolated nutrients, such as fatty acids, are not only difficult to perform, but also trade potential relevance for increased power. Thus, to approach questions dealing with the roles of specific nutrients, authors often rely on supplementation or on observational studies to seek correlations between study outcomes and specific biomarkers reflecting a nutrient's level of intake or metabolism. Interestingly, a meta-analysis of 13 randomized placebo-controlled trials enrolling a total of 1,233 patients with major depressive disorder (MDD) demonstrated a beneficial effect of omega-3 PUFA supplementation on depressive symptoms ([@B105]), with a larger effect at higher doses and in patients being simultaneously treated with antidepressants, suggesting a potential adjuvant role of omega-3 fatty acids in MDD treatment.

Results from several other meta-analyses and epidemiological studies suggest that reduced levels of PUFAs could be involved in the pathogenesis of cognitive and mood disorders, and may be therapeutic targets in those diseases. A meta-analysis of 14 studies found that subjects with depressive symptoms or social anxiety disorders had lower circulating levels of the n-3 PUFAs, eicosapentaenoic acid, 20:5n-3 (EPA) and docosahexaenoic acid, 22:6n-3 (DHA), and/or higher levels of the n-6 PUFA, arachidonic acid, 20:4n-6 (ARA), than control subjects ([@B87]). In addition, post-mortem analysis of orbitofrontal and prefrontal cortex of patients with major depression showed lower DHA levels compared to controls ([@B101], [@B102]). Moreover, a recent 7-year follow-up study of 69 young individuals with an ultra-high risk phenotype for psychosis demonstrated that lower levels of EPA and/or DHA, and higher n-6/n-3 PUFA ratio in the phosphatidylethanolamine fraction of erythrocyte membranes, specifically predicted mood disorders (in this cohort, 24 patients received a diagnosis of MDD and 2 of bipolar disorder during the follow-up period; [@B10]). Altogether, these and other studies implicate PUFAs in the pathogenesis of mood and cognitive disorders, providing a basis for nutritional psychiatry approaches in these highly prevalent and incapacitating diseases.

High-Fat Diet in Rodent Models
==============================

Many of the current inferences on the impact of HFD on human health have been based on or influenced by studies in animal models, mostly rodents. As in humans, fat-enriched diets induce rapid weight gain and metabolic alterations in animal models. Although the term 'high-fat diet' is widely used to describe studies in which fat corresponds to the highest proportion of energy intake, that percentage may range from 20 to 60% of total energy intake and diet composition may include animal-derived fats or plant oils. Moreover, the composition of the control diet is often not standardized, with non-purified chow being used as a control and some studies omitting to mention the composition of the control diet altogether ([@B15]; [@B53]). Further, the age at which exposure to HFD is initiated is also variable among studies. Lack of standardization in studies under the HFD umbrella leads to great variability in observed outcomes and difficulty in establishing comparisons between studies.

Despite the different protocols, some of the effects of excess fat in the diet appear to be central and robust in mice. In a landmark report by [@B164], for instance, obesity induced in C57BL/6J mice by long-term exposure to a HFD (containing up to 60% calories from fat) produced increases in adipocyte number and size, body weight, fasting blood glucose levels, and induced hyperinsulinemia ([@B164]). Those metabolic changes were later shown to occur even after a short period of fat-enriched diet consumption ([@B86]).

[@B61] demonstrated a central role of TNF-α in diabetes and obesity-induced insulin resistance, using db/db, ob/ob, tub/tub, and fa/fa mice, genetic models of metabolic disorders (recently reviewed in [@B74]). In those mice, [@B61] showed that increased expression of TNF-α in adipocytes as well as high levels of this cytokine in the circulation resulted in insulin resistance. In line with those findings, [@B164] went on to show that excessive macrophage recruitment and upregulated expression of ADAM8, MIP-1α, MCP-1, MAC-1, F4/80, and CD68 in white adipose tissue contribute to the establishment of chronic inflammation and increased production and release of pro-inflammatory cytokines, notably TNF-α and IL-6, into the circulation. These results were later corroborated by others, and positioned obesity-induced inflammation into a broader picture ([@B61]; [@B160]; [@B164]; [@B96]; [@B39]).

The HFD mouse model has been instrumental in dissecting the molecular mechanisms involved in FFA-induced T2DM. It was first shown in humans that excessive FFAs in the circulation inhibit insulin signaling and glucose metabolism in several tissues, such as adipocytes, liver, and muscle. Excessive FFAs were shown to reduce muscle glucose transport and metabolism via decreased GLUT4 translocation to the plasma membrane ([@B134]) and to inhibit insulin signaling by increasing IRS-1 serine phosphorylation and reducing insulin-stimulated PI3-kinase activity ([@B46]; [@B36]). The important role of inflammatory responses in this process, which culminate in the activation of stress kinases such as JNK and IKKβ, which in turn target IRS, was described in HFD mouse models ([@B171]; [@B58]; [@B3]).

Increased saturated FFAs, observed in obesity and high fat intake models, have an intrinsic pro-inflammatory potential that impacts important cell functions. Fatty acids may activate Toll-like receptor 4 (TLR4) signaling in adipocytes and macrophages and induce inflammatory signaling ([@B142]), and mice lacking TLR4 were shown to be protected against high-fat diet-induced obesity and insulin resistance ([@B127]; [@B28]). TLRs are a family of type I transmembrane receptors that recognize a variety of microbial danger-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) and orchestrate an intracellular signaling response, playing an important role in infectious and inflammatory disorders. Amongst at least 13 members of TLRs described in mammals, TLR2 and TLR4 are best characterized in terms of their involvement in the immune response ([@B43]). TLR4 plays a critical role in the innate immune system by activating MyD88-dependent and MyD88-independent proinflammatory signaling pathways, as well as the NFκB response ([@B92]).

Mood disorders cannot be fully reproduced in rodent models. In addition to their incompletely understood etiology, they involve symptoms that may not exist outside of the human experience, such as inappropriate guilt and suicidality ([@B78]). However, rodent models may exhibit depressive-like symptoms, such as behavioral correlates of hopelessness or anhedonia. Recent data on rats and mice fed HFD suggest a positive association between HFD and such depressed phenotypes ([@B166]; [@B2]; [@B54]), which may be causally linked to diet-induced inflammatory processes, as discussed below.

Saturated Fatty Acids and Neuroinflammation: Possible Links to Mood Disorders
=============================================================================

Microglial cells respond rapidly to pathological changes in the brain, altering their morphology and phagocytic behavior, and increasing cytotoxic responses by secreting NO, proteases and cytokines, such as TNF-α and IL-1β ([@B77]). SFAs, such as palmitic acid, have been shown to induce activation of TLR4 receptors in hypothalamic microglia and to stimulate cytokine release ([@B154]), indicating a potential mechanism by which HFD leads to brain inflammation. Notably, the hippocampus---a key brain region involved not only in learning and memory but also in depression and the effect of antidepressants---is vulnerable to altered levels of IL-1β, IL-6, and TNF-α, as these cytokines have important roles in synaptic plasticity and may inhibit neurogenesis ([@B141]; [@B17]).

Microglia and astrocytes are essential to normal synaptic function. Synaptic pruning by microglia is essential to synaptic maturation and neurotransmission ([@B123]), while astrocytes hold important metabolic and plasticity functions ([@B9]; [@B144]). Importantly, HFD-induced depressive-like behavior in rodents, as well as cognitive impairment, has been associated with brain inflammation. For instance, [@B37] showed that, in addition to the classical metabolic alterations, rats fed an HFD (60% of calories as fat) for 16 weeks show anhedonic behavior, which presents alongside insulin signaling impairment and increased levels of cytokines such as IL-6, IL-1β, and TNF-α in the hippocampus. In turn, mice exposed to long term HFD were shown to have spatial memory deficits in the Morris water maze, with increased serum and hippocampal levels of TNF-α and presence of activated microglia in the hippocampus, as well as reduced dendritic branching and complexity ([@B55]; [@B68]).

In line with the structural similarity between SFAs and the lipid portion of bacterial lipopolysaccharide (LPS), several lines of evidence suggest that SFAs act as ligands of TLRs. *In vitro* experiments have shown that SFAs activate TLR2 to induce an inflammatory response ([@B41]; [@B64]), and numerous reports have linked SFAs to TLR4-mediated signaling pathways in immune cells ([@B124]; [@B135]). Using both the BV-2 microglial cell line and primary microglial cultures, [@B159] demonstrated that palmitic acid and stearic acid induce a reactive microglial phenotype and increase levels of inflammatory markers in a TLR4-dependent manner. The SFAs, lauric, palmitic, and stearic acids, but not unsaturated fatty acids or PUFAs, were shown to induce NF-κB activation and expression of COX-2 and other inflammatory markers in macrophages, effects inhibited in dominant-negative TLR4 cells ([@B85]). Further, the liver secretory protein fetuin-A (FetA) has been suggested as an adaptor protein between FFAs and TLR4 activation, connecting FFAs to TLR-mediated inflammation ([@B120]). Importantly, however, the role of TLRs as SFA receptors is still a matter of debate. The most recent challenge to this notion was a compelling report by [@B81] suggesting that SFAs are not direct ligands of TLR4 in macrophages, but instead contribute to pro-inflammatory signaling by altering lipid metabolism in these cells. They reconcile these results with past literature findings by showing that, despite not being a direct target, TLR4-dependent priming is a requirement for SFA-induced inflammatory signaling.

Inflammation has emerged as an important factor in mood disorders. Patients presenting mood disorders show elevated plasma levels of cytokines such as TNF-α, IL-6, and IL-1β, as well as increased expression of inflammatory markers in blood cells (reviewed by [@B103]). Increased consumption of high fat diet is related to depressive-like behavior and emotional disorders in mice ([@B158]; [@B2]; [@B153]; [@B165]), and neuroinflammation could be an important modulator of these behavioral alterations. Palmitic acid abolished the migration and phagocytic activity of microglia in response to interferon-γ, thus affecting the protective response of these cells after an inflammatory challenge *in vitro* ([@B168]). Post-mortem analysis of brain tissue from MDD patients indicated a 6.5% increase in palmitic acid and a 6.2% decrease in oleic acid in the amygdala, as compared to controls ([@B52]), further suggesting that altered levels of specific fatty acids may be implicated in brain dysfunction.

One potential mechanistic connection between neuroinflammation and mood disorders is the positive effect of pro-inflammatory cytokines on microglial expression of indolamine-2,3-dioxygenase (IDO), the enzyme that converts tryptophan to kynurenine ([@B161]; [@B26]). Lower availability of tryptophan in the brain due to upregulation of this alternative pathway could slow down its conversion to 5-hydroxytryptophan, the rate-limiting step in serotonin synthesis, carried out by tryptophan hydroxylase. Notably, while far from the only factor involved, serotonin depletion has been shown to induce depressive-like symptoms in animal models and impact mood in humans under certain conditions ([@B137]; [@B114]). Furthermore, increased kynurenine metabolism may result in excessive production of 3-hydroxykynurenine, a generator of reactive oxygen species (ROS), and quinolinic acid, an NMDA receptor agonist, both of which could have their own implications to depression ([@B112]).

Another possible mechanism linking neuroinflammation to mood involves precisely the vulnerability of monoaminergic pathways to oxidative stress. Tetrahydrobiopterin (BH~4~) is an essential cofactor, required for certain enzymatic reactions such as those carried out by tryptophan hydroxylase, phenylalanine hydroxylase (which coverts phenylalanine to tyrosine) and tyrosine hydroxylase (which converts tyrosine to [L]{.smallcaps}-DOPA, the rate limiting step in dopamine synthesis). BH~4~ may be readily inactivated by ROS, a likely event in strong proinflammatory contexts, thus affecting dopamine and serotonin levels (reviewed by [@B150]). Notably, in addition to the role of serotonin mentioned above, recent reports have shown that dopamine neurotransmission, particularly in the ventral tegmental area-nucleus accumbens circuit, is essential for the expression of depressed phenotypes and social behavior, and thus its depletion could contribute to mood disorders ([@B151]; [@B49]; [@B100]).

Polyunsaturated Fatty Acids, Neuroinflammation and Links to Mood Disorders
==========================================================================

The nutritional transition observed worldwide in the past few decades has introduced high amounts of SFAs and omega-6 (n-6) PUFAs in the human diet through increased intake of dairy products, vegetable oils and red meat. This change in dietary profile was further accompanied by a reduction in consumption of fruits, vegetables, legumes, grains and fish, important sources of omega-3 (n-3) PUFAs. These changes resulted in an increase in omega-6/omega-3 ratio from about 1:1 to 10:1, reaching up to 20--25:1 or higher, and an alarming omega-3 deficiency in the global population, mainly in Western countries ([@B143]).

Omega-3 and omega-6 PUFAs are categorized in these two groups according to the position of the double bond closest to the methyl terminus of the hydrocarbon chain, and, together, comprise the very-long chain family of polyunsaturated fatty acids (VLC-PUFAs). The main VLC-PUFAs in humans are the omega-3 PUFAs, EPA and DHA, and the omega-6 PUFA, ARA, which are components of membrane phospholipids and important signaling molecules ([@B172]). In humans, VLC-PUFAs are endogenously synthesized in small amounts from dietary intake of the essential fatty acids, linoleic acid (LA) and alpha-linolenic acid (ALA). These are precursors of ARA, EPA, and DHA synthesis through the action of elongase and desaturase enzymes, which successively elongate and include double bonds into the carbon chain. Thus, adequate balance of these nutrients in the diet is necessary for healthy development, survival and aging ([@B19]).

The brain is a lipid-rich organ, and approximately 35% of those lipids are PUFAs ([@B169]). DHA and ARA are major PUFA components in brain cells. They are predominantly found esterified as glycerophospholipids at the plasma membrane (approximately 10,000 nmol per gram of brain tissue) but are also found at much lower amounts in non-esterified form (about 1 nmol per gram of brain tissue). They act as structural components and signaling molecules in neurons, glial cells, and endothelial cells ([@B8]). Studies in humans and, mainly, in animal models have revealed that PUFAs enter the brain via lipoproteins or albumin transport in esterified form, as lysophosphatidylcholine, or in non-esterified form, by passive diffusion through a flip-flop mechanism or through protein transporters, such as fatty acid binding proteins (FABPs), fatty acid transport protein (FATP), fatty acid translocases (FAT/CD36) and major facilitator superfamily domain-containing protein 2 (Mfsd2a) ([@B82]; [@B152]; [@B35]; [@B113]; [@B22]; [@B89]; [@B121], [@B122]; [@B50]). PUFAs play important roles in brain function, including synaptic plasticity, neurotransmission, metabolism, neurogenesis, neuroinflammation and neuroprotection ([@B8]). Not surprisingly, therefore, reduced or unbalanced dietary supply and brain levels of PUFAs (notably, DHA) are associated with brain disorders, including cognitive and mood disorders (see below).

In addition to modulation of serotonin (5-HT1 and 5-HT4), beta-adrenergic and dopamine (D1 and D2) receptor signaling through increased adenylate cyclase and protein kinase A (PKA) activities ([@B89]), PUFAs play an important role in neuroinflammation, an important etiologic factor of mood disorders ([@B21]; [@B170]; [@B23]). Omega-6 and omega-3 PUFAs have opposite effects on inflammatory modulation. ARA is an important precursor of eicosanoids, bioactive molecules that regulate the inflammatory process in immune cells. In response to inflammatory stimuli, membrane phospholipids are cleaved by phospholipase A2 (PLA-2) and release ARA, a substrate of cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450. This stimulates synthesis of prostaglandins (PGs), thromboxanes (TXs), and leukotrienes (LTs), key pro-inflammatory mediators ([@B65]). Post-mortem analysis of brains from patients with bipolar disorders indicated a dysregulation of ARA release and downstream metabolism in frontal cortex ([@B73]), and mood stabilizers such as lithium, valproate and carbamazepine have been found to modify the ARA cascade in the brain ([@B73]). These findings suggest that increased levels of ARA from the diet could lead to exacerbation and dysregulation of the inflammatory response in brain cells, thus contributing to mechanisms associated with mood disorders.

*In vitro* studies showed that omega-3 PUFAs modulate microglial functions. For instance, EPA treatment inhibited microglial production of proinflammatory cytokines (IL-1β, IL-6, and TNF-α) ([@B90]) *in vitro*, and supplementation with omega-3 PUFAs inhibited microglial activation and shifted microglial profile from the so-called classical pro-inflammatory M1 to the neuroprotective M2 phenotype in a model of brain injury in rats ([@B23]). When incorporated into microglial membranes, DHA, which has been described as a potent immunomodulator in brain cells ([@B1]), blocked the recognition of LPS by cell surface receptors and inhibited nuclear factor kappa B (NF-κB) activation and synthesis of IL-1β and TNF-α ([@B33]). In addition, DHA prevented LPS-induced neuroinflammation and restored synaptic structure and functions in hippocampal CA1 pyramidal neurons ([@B21]). In Fat-1 mice, which convert n-6 to n-3 PUFAs in the brain, feeding with a DHA-enriched diet prevented LPS-induced increases in pro-inflammatory cytokines, microglial activation, depressive-like behavior and reduction in BDNF levels ([@B48]).

Omega-3 PUFAs, mainly EPA, are competitive substrates for enzymes involved in the biosynthesis of inflammatory mediators derived from ARA. Increased PUFA consumption results in a membrane phospholipid composition with increased levels of these fatty acids, and in a reduction of ARA-derived inflammatory mediators (reviewed in [@B18]). Moreover, DHA and EPA are precursors of important lipid mediators with anti-inflammatory and pro-resolutive actions, such as resolvins and protectins. Resolvin D1 (RvD1) and resolvin E1 (RvE1), for example, decrease LPS-induced microglial expression of proinflammatory cytokines, namely TNF-α, IL-6, and IL-1β ([@B133]).

Fatty Acids, Microbiota Changes, and Mood Disorders
===================================================

Recently, the gut--microbiota--brain axis has been implicated in neuroinflammation and the development of neuropsychiatric disorders. A comparative analysis between children from a rural African village in Burkina Faso (fed a rural diet) and European children (fed a modern Western diet) indicated significant differences in gut microbiota between the two groups ([@B32]), and suggested an important role of the nutritional transition in altering the human gut microbiome and in the development of inflammatory diseases.

The gut microbiome rapidly responds to dietary composition. Using mouse models, David et al. showed that short-term exposure to diets enriched in animal or plant products changed microbiota composition and microbial gene expression ([@B27]). Feeding a HFD caused shifts in the gut bacterial ecosystem in mice ([@B25]). More recently, mice fed a HFD for 8 weeks were shown to present a depressive-like phenotype accompanied by a relative reduction in the population of Bacteroidetes and increase in the population of Firmicutes and Cyanobacteria in their caecal microbiome ([@B54]). Interestingly, MDD patients showed different abundances of Firmicutes, Actinobacteria and Bacteroidetes when compared to healthy controls. In the same study, transplantation of fecal microbiota from MDD patients into mice resulted in depressive-like behaviors compared with colonization with microbiota derived from healthy control individuals ([@B173]). Similarly, transplantation of fecal microbiota from depressed patients to microbiota-depleted rats induced anhedonia and anxiety-like behaviors ([@B71]).

The detailed mechanisms underlying how changes in microbiota may lead to mood disorders remain unclear, but neuroinflammation appears as a potential mechanism. Microglia from germ-free mice showed decreased expression of genes associated with inflammation and defense responses, and an immature profile when compared with microglia from control mice ([@B99]; [@B45]). Moreover, microbiota complexity has a central role in microglia function, regulating the neuroinflammatory response in health and disease ([@B40]).

Adiponectin
===========

Adiponectin, a hormone released by adipocytes and found abundantly in plasma and at lower concentrations in the CSF ([@B38]), has been linked to mood disorders, and may connect dietary changes to behavior, particularly with respect to long-term effects. Circulating levels of adiponectin and the response elicited by activation of its receptors, AdipoR1 and AdipoR2 (found in several organs, including the brain), have been shown to be modulated by inflammatory and metabolic conditions, such as obesity and diabetes ([@B62]; [@B167]). Although consistent human data are lacking, adiponectin has anti-depressant ([@B88]) and anti-inflammatory ([@B118]) properties in mice. It has also been shown to be a candidate mediator of the positive effects of exercise and environmental enrichment on neurogenesis, mood, and cognition ([@B20]).

The Insulin-Dopamine Link
=========================

[@B75] showed that reduced insulin signaling in the brain, as a result of insulin resistance, led to increased levels of monoamine oxidases and increased dopamine clearance. They further showed that this change in dopamine metabolism led to age-related anxiety and depressive-like behavior in mice, results consistent with the above mentioned increasingly important role of dopamine signaling in mood disorders.

Complementing their previous results ([@B75]), the same group later used conditional insulin receptor knockout mice to show that insulin signaling in astrocytes has a role in regulating dopaminergic transmission, via the release of the gliotransmitter ATP ([@B16]). Their results suggest that activation of insulin receptors in astrocytes activates Munc18c to promote ATP exocitosis, which acts on P2X receptors on dopaminergic neurons to modulate dopamine release and normal mood behavior. These results also led to the conclusion that dopamine signaling may be altered and contribute to mood disorders in an insulin resistance scenario ([@B16]).

Moreover, [@B44] demonstrated in mice that prolonged consumption of an HFD impairs insulin signaling in the nucleus accumbens and reduces dopamine reuptake in dopaminergic terminals. Notably, restoring insulin signaling could revert this deficit, suggesting that loss of insulin sensitivity may be the cause of altered dopaminergic in the region ([@B44]).

Perspectives and Concluding Remarks
===================================

Given the high rate of failure of antidepressant therapies, with at least 30% of patients being unresponsive to multiple rounds of pharmacological treatment ([@B145]), and the lack of effective, disease modifying treatments for dementia, the prospect of dietary interventions for mood and cognitive disorders is appealing. Notably, the targets involved in potential dietary approaches to mental health may in fact overlap with targets for pharmacotherapy in current clinical trials, including neuroinflammation (e.g., TLR and cytokine receptors) and brain insulin signaling ([Figure 1](#F1){ref-type="fig"}). To reach this goal, an important step will be to understand and dissect the distinct but interdependent roles of fatty acids as nutrients and signaling molecules in the brain, and their impact on brain function and dysfunction. Finally, since no food is consumed in isolation by humans, this should happen as part of a larger effort to explore the already proposed potential of other nutrients, particularly carbohydrates, as competing players in both inflammation and insulin signaling ([@B34]).

![Pathways linking diet and mental health. The nutritional transition observed in modern society, mainly in Western countries, has resulted in increased consumption of SFAs and reduced intake of PUFAs. Excessive energy intake from fat-enriched diets increases fatty acid storage and surpasses the remodeling capacity of adipose tissue, resulting in macrophage recruitment and increasing circulating levels of proinflammatory cytokines. Increased cytokine levels lead to the activation of stress kinases, such as JNK and IKKβ, resulting in increased IRS-1 serine phosphorylation and reduced insulin-stimulated PI3-kinase activity, causing central and peripheral insulin resistance. Brain inflammation and insulin resistance have been implicated in cognitive deficits (reviewed in [@B31]; [@B42]). A recent report further suggested that reduced insulin signaling in the brain affects dopamine metabolism and release, contributing to mood disorders ([@B16]). Whether this dopaminergic dysfunction is also related to cognitive impairment is a possibility yet unexplored. Excessive energy intake from dietary fat further results in dysregulation of free fatty acid (FFA) fluxes, reducing PUFAs and increasing SFAs in the circulation. Although the exact mechanism is still controversial ([@B81]), several reports have shown that SFAs activate TLR4-dependent signaling pathways that increase inflammatory responses in microglia and induce brain inflammation, another potential mechanism involved in the development of both mood disorders and cognitive impairment. At the same time, dietary choices are known to impact the gut microbiota, which may regulate neuroinflammatory responses. Together, these interconnecting mechanisms suggest relevant links between lipid imbalance associated with fat-enriched diets and the onset and progression of neuropsychiatric and cognitive disorders.](fnins-13-00265-g001){#F1}
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